OPEN PROSPECTIVE TRIAL INVESTIGATING PHARMACOKINETICS, TOLERABILITY AND SAFETY OF A NEW 10% HUMAN IMMUNOGLOBULIN FOR INTRAVENOUS INFUSION (IVIG) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASE

被引：0
|
作者：
Krivan, G. [1 ]
Koenigs, C. [2 ]
Bernatowska, E. [3 ]
Marodi, L. [4 ]
Erdos, M. [4 ]
Salama, A. [5 ]
Linde, R. [2 ]
机构：
[1] United St Istvan & St Laszlo Hosp, Dept Pediat Hematol & Stem Cell Transplantat, Budapest, Hungary
[2] Goethe Univ Frankfurt, Dept Pediat Hemostasis & Immunodeficiency, Frankfurt, Germany
[3] Childrens Mem Hlth Inst, Dept Immunol, Warsaw, Poland
[4] Univ Debrecen, Med & Hlth Sci Ctr, Dept Infectol & Pediat Immunol, H-4012 Debrecen, Hungary
[5] Univ Med Berlin, Inst Transfus Med, Berlin, Germany
来源：
JOURNAL OF CLINICAL IMMUNOLOGY | 2012年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：154 / 154
页数：1
相关论文
共 50 条
  • [1] An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease
    Krivan, G.
    Koenigs, Ch.
    Bernatowska, E.
    Salama, A.
    Wartenberg-Demand, A.
    Sonnenburg, C.
    Linde, R.
    VOX SANGUINIS, 2015, 109 (03) : 248 - 256
  • [2] AN OPEN, PROSPECTIVE TRIAL INVESTIGATING THE PHARMACOKINETICS AND SAFETY, AND THE TOLERABILITY OF ESCALATING INFUSION RATES OF A 10% HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS INFUSION (IVIG), BT090, IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASE
    Krivan, G.
    Koenigs, Ch.
    Bernatowska, E.
    Salama, A.
    Wartenberg-Demand, A.
    Sonnenburg, C.
    Linde, R.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (06) : 699 - 700
  • [3] Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
    Richard L. Wasserman
    Joseph A. Church
    Mark Stein
    James Moy
    Martha White
    Steven Strausbaugh
    Harry Schroeder
    Mark Ballow
    James Harris
    Isaac Melamed
    David Elkayam
    William Lumry
    Daniel Suez
    Syed M. Rehman
    Journal of Clinical Immunology, 2012, 32 : 663 - 669
  • [4] Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
    Wasserman, Richard L.
    Church, Joseph A.
    Stein, Mark
    Moy, James
    White, Martha
    Strausbaugh, Steven
    Schroeder, Harry
    Ballow, Mark
    Harris, James
    Melamed, Isaac
    Elkayam, David
    Lumry, William
    Suez, Daniel
    Rehman, Syed M.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (04) : 663 - 669
  • [5] Efficacy, Pharmacokinetics And Tolerability Of IQYMUNE®, A Novel 10% Intravenous Immunoglobulin (IVIg), In Patients With Primary Immunodeficiency(PID
    Krivan, Gergely
    Chernyshova, Ludmila
    Kostyuchenko, Larysa
    Lange, Andrzej
    Nyul, Zoltan
    Derfalvi, Beata
    Musial, Jacek
    Bellon, Anne
    Kappler, Martin
    Sadoun, Alain
    Puget, Sophie
    Bernatowska, Ewa
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2015, 182 : 19 - 19
  • [6] Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease
    Krivan, Gergely
    Borte, Michael
    Harris, James B.
    Lumry, William R.
    Aigner, Silke
    Lentze, Stephan
    Staiger, Christiane
    VOX SANGUINIS, 2022, 117 (10) : 1153 - 1162
  • [7] Clinical Studies Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of a New Human Plasma-Derived Intravenous Immunoglobulin Product ("NEWGAM 10%") in Patients with Primary Immunodeficiency Disease
    Borte, M.
    Wietek, S.
    Pyringer, B.
    Svae, T. E.
    Moy, J.
    Melamed, I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S304 - S304
  • [8] Efficacy, Pharmacokinetics, Safety, and Tolerability of FlebogammaA® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency
    Berger, Melvin
    Pinciaro, Paul J.
    Althaus, Arthur
    Ballow, Mark
    Chouksey, Akhilesh
    Moy, James
    Ochs, Hans
    Stein, Mark
    JOURNAL OF CLINICAL IMMUNOLOGY, 2010, 30 (02) : 321 - 329
  • [9] Efficacy, Pharmacokinetics, Safety, and Tolerability of Flebogamma® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency
    Melvin Berger
    Paul J. Pinciaro
    Arthur Althaus
    Mark Ballow
    Akhilesh Chouksey
    James Moy
    Hans Ochs
    Mark Stein
    Journal of Clinical Immunology, 2010, 30 : 321 - 329
  • [10] Open, prospective, multicentre study on clinical efficacy, safety, and pharmacokinetics; of the human normal immunoglobulin for intravenous administration BT681 in patients with primary immunodeficiency disease
    Wolf, D. M.
    Bernatowska, E.
    Kreuz, W.
    Marodi, L.
    Rossi, P.
    Espanol Boren, T.
    Sonnenburg, C.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2008, 154 : 98 - 98
12345